Pharmaceutical TechnologyOriginal article
Intismeran autogene a turning point for cancer vaccines
Phase 3intismeran autogeneNeutral
AI Analysis
Summary
Moderna announced interim analysis data from a Phase III trial for intismeran autogene, a personalized mRNA neoantigen cancer vaccine, on August 19, 2026.
Clinical Trial Data
Phase
Phase III
Outcome Details
interim analysis data announced
Importance:7/10
Sentiment:
0.00
mRNAcancer vaccinepersonalized medicineneoantigen
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 21, 2026 2:18 PM